Microbiome Report for Week Ending 2/9/19

Seres Therapeutics Reduces Workforce by 30% to Focus on Advancing Clinical Assets
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on 2/7/19 certain corporate changes to focus resources on its highest priority, clinical-stage microbiome therapeutic candidates.